Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Extension Study of ABP-671 in Participants With Gout
NCT06276556 · Atom Therapeutics Co., Ltd · PHASE2/PHASE3 · terminated · last registry update 2025-07-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “For business consideration, a new long-term safety study will be conducted in the next new pivotal studies.” | – | Registry record, Atom Therapeutics Co., Ltd |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XDH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-10Results posted on the registry: Urica Therapeutics Inc., dotinurad + dotinurad + allopurinol (NCT06056570)
- 2026-05-07Phase 3 first posted: Tanta University, Sertraline 50 MG + Allopurinol 300 MG (NCT07574060)
- 2026-02-17Phase 3 first posted: Innovent Biologics Technology Limited (Shanghai R&D Center), Febuxostat + Tigulixostat (NCT07414394)
- 2026-01-30Results posted on the registry: University of Florida, Phentermine / Topiramate Oral Product + Citrate Salts, Allopurinol, Diet (NCT04621929)
- 2025-07-30Results posted on the registry: Eisai Co., Ltd., Dotinurad + Febuxostat (NCT05007392)
- 2025-07-28Phase 3 first posted: Crystalys Therapeutics, Allopurinol + Dotinurad (NCT07089875)
- 2025-07-28Phase 3 first posted: Crystalys Therapeutics, Allopurinol + Dotinurad (NCT07089888)
- 2025-05-29Results posted on the registry: Gilead Sciences, Magrolimab + Rituximab (NCT02953509)
- 2025-05-29Also stopped (terminated): Gilead Sciences, Magrolimab + Rituximab (NCT02953509)
- 2024-12-05Also stopped (terminated): Washington University School of Medicine, Mycophenolate Mofetil + Allopurinol (NCT05049863)
- 2024-09-19Phase 3 first posted: Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd, Febuxostat 20MG Tablets + Febuxostat 20MG Placebo (NCT06603142)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision